Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Compare
Compare
Traded in other countries / regions
LLY.Argentina
•
LLYC.Austria
•
LILY34.Brazil
•
LLY.France
•
LLY.Germany
•
LLY.Mexico
•
LLY.Switzerland
•
LEL.UK
•
LLY.USA
Description
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 1.97 | |||||
| Debt-to-EBITDA | 2.06 | |||||
| Interest Coverage | 26.2 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 5.89 | |||||
| Beneish M-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.3 | |||||
| 3-Year EBITDA Growth Rate | 18.1 | |||||
| 3-Year EPS without NRI Growth Rate | 26.1 | |||||
| 3-Year FCF Growth Rate | 34.6 | |||||
| 3-Year Book Growth Rate | 0.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 18.98 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 7.02 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.32 | |||||
| 9-Day RSI | 30.01 | |||||
| 14-Day RSI | 36.68 | |||||
| 6-1 Month Momentum % | 37.9 | |||||
| 12-1 Month Momentum % | 22.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | |||||
| Quick Ratio | 0.85 | |||||
| Cash Ratio | 0.18 | |||||
| Days Inventory | 202.9 | |||||
| Days Sales Outstanding | 78.1 | |||||
| Days Payable | 82.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.22 | |||||
| Dividend Payout Ratio | 0.58 | |||||
| 3-Year Dividend Growth Rate | 14.8 | |||||
| Forward Dividend Yield % | 1.31 | |||||
| 5-Year Yield-on-Cost % | 2.07 | |||||
| 3-Year Average Share Buyback Ratio | 3.4 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.98 | |||||
| Operating Margin % | 29.84 | |||||
| Net Margin % | 19.58 | |||||
| ROE % | 69.31 | |||||
| ROA % | 11.92 | |||||
| ROIC % | 22.33 | |||||
| ROC (Joel Greenblatt) % | 70.35 | |||||
| ROCE % | 19.77 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 48.7 | |||||
| Forward PE Ratio | 36.86 | |||||
| PE Ratio without NRI | 48.7 | |||||
| Shiller PE Ratio | 64.18 | |||||
| Price-to-Owner-Earnings | 96.61 | |||||
| PEG Ratio | 2.52 | |||||
| PS Ratio | 9.4 | |||||
| PB Ratio | 33.47 | |||||
| Price-to-Free-Cash-Flow | 55.26 | |||||
| Price-to-Operating-Cash-Flow | 38.48 | |||||
| EV-to-EBIT | 45.72 | |||||
| EV-to-Forward-EBIT | 36.2 | |||||
| EV-to-EBITDA | 36.71 | |||||
| EV-to-Forward-EBITDA | 31.12 | |||||
| EV-to-Revenue | 10.32 | |||||
| EV-to-Forward-Revenue | 10.51 | |||||
| EV-to-FCF | 61.32 | |||||
| Price-to-Projected-FCF | 4.03 | |||||
| Price-to-Median-PS-Value | 2.19 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.2 | |||||
| Earnings Yield (Greenblatt) % | 2.19 | |||||
| Forward Rate of Return (Yacktman) % | 21.45 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:LLY
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29,070.7 | ||
| EPS (TTM) ($) | 6.18 | ||
| Beta | 0.4 | ||
| Volatility % | 27.74 | ||
| 14-Day RSI | 36.68 | ||
| 14-Day ATR ($) | 7.406676 | ||
| 20-Day SMA ($) | 320.606 | ||
| 12-1 Month Momentum % | 22.65 | ||
| 52-Week Range ($) | 220.2 - 335.33 | ||
| Shares Outstanding (Mil) | 950.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||